Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
CD38-targeted antibody, daratumumab, is approved for the treatment of multiple myeloma (MM). Phase 1/2 studies GEN501/SIRIUS revealed a novel immunomodulatory mechanism of action (MOA) of daratumumab that enhanced the immune response, reducing natural killer (NK) cells without affecting efficacy or safety. We further evaluated daratumumab’s effects on immune cells in whole blood samples of relapsed/refractory MM patients from both treatment arms of the phase 3 POLLUX study (lenalidomide/dexamethasone [Rd] or daratumumab plus Rd [D-Rd]) at baseline (D-Rd, 40; Rd, 45) and after 2 months on treatment (D-Rd, 31; Rd, 33) using cytometry by time-of-flight. We confirmed previous reports of NK cell reduction with D-Rd. Persisting NK cells were phenotypically distinct, with increased expression of HLA-DR, CD69, CD127, and CD27. The proportion of T cells increased preferentially in deep responders to D-Rd, with a higher proportion of CD8+versus CD4+T cells. The expansion of CD8+T cells correlated with clonality, indicating generation of adaptive immune response with D-Rd. D-Rd resulted in a higher proportion of effector memory T cells versus Rd. D-Rd reduced immunosuppressive CD38+regulatory T cells. This study confirms daratumumab’s immunomodulatory MOA in combination with immunomodulatory drugs and provides further insight into immune cell changes and activation status following daratumumab-based therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bendall, S. C., Simonds, E. F., Qiu, P., Amir, E.-A. D., Krutzik, P. O., Finck, R., Bruggner, R. V., Melamed, R., Trejo, A., Ornatsky, O. I., et al. (2011) · Science · doi:10.1126/science.1198704 · Cited by 2,279
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445
Self-citationBandura, D. R., Baranov, V. I., Ornatsky, O. I., Antonov, A., Kinach, R., Lou, X., Pavlov, S., Vorobiev, S., Dick, J. E., & Tanner, S. D. (2009) · Analytical Chemistry · doi:10.1021/ac901049w · Cited by 1,295
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117
Self-citationde Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Self-citationExtracting a cellular hierarchy from high-dimensional cytometry data with SPADE
Qiu, P., Simonds, E. F., Bendall, S. C., Gibbs, K. D., Bruggner, R. V., Linderman, M. D., Sachs, K., Nolan, G. P., & Plevritis, S. K. (2011) · Nature Biotechnology · doi:10.1038/nbt.1991 · Cited by 956
Lonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854
Self-citationOverdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521
Self-citationOverdijk, M. B., Jansen, J. H. M., Nederend, M., Lammerts van Bueren, J. J., Groen, R. W. J., Parren, P. W. H. I., Leusen, J. H. W., & Boross, P. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501351 · Cited by 297
Postow, M. A., Manuel, M., Wong, P., Yuan, J., Dong, Z., Liu, C., Perez, S., Tanneau, I., Noel, M., Courtier, A., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0070-4 · Cited by 232
Cited by
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
Kastritis, E., Palladini, G., Minnema, M. C., Wechalekar, A. D., Jaccard, A., Lee, H. C., Sanchorawala, V., Gibbs, S., Mollee, P., Venner, C. P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028631 · Cited by 702
Self-citationDaratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312054 · Cited by 599
Self-citationFacon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00466-6 · Cited by 370
Self-citationDimopoulos, M. A., Terpos, E., Boccadoro, M., Delimpasi, S., Beksac, M., Katodritou, E., Moreau, P., Baldini, L., Symeonidis, A., Bila, J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00128-5 · Cited by 344
Self-citationSan-Miguel, J., Avet-Loiseau, H., Paiva, B., Kumar, S., Dimopoulos, M. A., Facon, T., Mateos, M.-V., Touzeau, C., Jakubowiak, A., Usmani, S. Z., et al. (2022) · Blood · doi:10.1182/blood.2020010439 · Cited by 153
Self-citation
Metadata
- Authors
- Casneuf, T., Adams, H. C., van de Donk, N. W. C. J., Abraham, Y., Bald, J., Vanhoof, G., Van der Borght, K., Smets, T., Foulk, B., Nielsen, K. C., Rusbuldt, J., Axel, A., Lysaght, A., Ceulemans, H., Stevenaert, F., Usmani, S. Z., Plesner, T., Avet-Loiseau, H., Nijhof, I., Mutis, T., Schecter, J. M., Chiu, C., & Bahlis, N. J.
- Venue
- Leukemia
- Published
- 2020-05-26
- Volume
- 35
- Issue
- 2
- Pages
- 573-584
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W3032537564
- Cited by
- 121
- References
- 11
- FWCI
- 9.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. https://app.cochat.ai/papers/10.1038/s41375-020-0855-4
- The paper
- Casneuf, T., Adams, H. C., van de Donk, N. W. C. J., Abraham, Y., Bald, J., Vanhoof, G., Van der Borght, K., Smets, T., Foulk, B., Nielsen, K. C., Rusbuldt, J., Axel, A., Lysaght, A., Ceulemans, H., Stevenaert, F., Usmani, S. Z., Plesner, T., Avet-Loiseau, H., Nijhof, I., . . . Bahlis, N. J. (2021). Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. Leukemia. https://doi.org/10.1038/s41375-020-0855-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.